Staging of gastric cancer with the Clinical Stage Prediction score

Kiyoaki Taniguchi, Masaho Ota, Takuji Yamada, Akiko Serizawa, Takeharu Noguchi, Kunihiko Amano, Sho Kotake, Shunichi Ito, Naoki Ikari, Akiko Omori, Masakazu Yamamoto

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Background: Chemotherapy with or without surgery is the first-line treatment for stage III/IV gastric cancer, while surgery is the first-line treatment for stage I/II gastric cancer. Accordingly, it is important to distinguish between stage III/IV and stage I/II gastric cancer, but clinical staging is less accurate than pathological staging. This study was performed to develop a clinical score that could distinguish stage III/IV gastric cancer from stage I/II gastric cancer. Methods: We reviewed 2722 patients who underwent gastrectomy at our hospital from January 1996 to December 2015. As pretreatment factors potentially related to tumor stage, we assessed age, sex, tumor markers, tumor diameter, tumor location, tumor histology, and macroscopic type. Factors showing significance on multivariate analysis were used to develop the Clinical Stage Prediction score (CSP score), and a cutoff value for the score was determined by receiver operating characteristics analysis. Results: According to multivariate analysis, clinical factors associated with stage III/IV disease were elevation of the carcinoembryonic antigen level, tumor diameter ≥ 60 mm, circumferential gastric involvement, esophageal infiltration, mucinous adenocarcinoma, and macroscopic types 2-4. The CSP score was obtained by weighting these factors according to the non-standardized β-coefficient. Receiver operating characteristics analysis indicated that the optimum cutoff value of the CSP score was 17 points. Among 1042 patients with a CSP score ≥ 17 points, 820 patients (78.7%) had stage III/IV gastric cancer. Conversely, among 1680 patients with a CSP score < 17 points, 1547 patients (92.1%) had stage I/II gastric cancer. When discrimination of stage III/IV gastric cancer from stage I/II gastric cancer by the CSP score was assessed, the sensitivity was 78.7%, specificity was 92.1%, positive predictive value was 86.0%, and negative predictive value was 87.5%. Conclusions: The CSP score can be helpful for differentiating stage III/IV gastric cancer from stage I/II gastric cancer based on pretreatment clinical factors.

Original languageEnglish
Article number47
JournalWorld Journal of Surgical Oncology
Volume17
Issue number1
DOIs
Publication statusPublished - 08-03-2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Staging of gastric cancer with the Clinical Stage Prediction score'. Together they form a unique fingerprint.

Cite this